
 Europäisches Patentamt
 European Patent Office
 Office européen des brevets

(11) Publication number:

0 093 551

A2



(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 83302290.8

(22) Date of filing: 22.04.83

(51) Int. Cl.³: **A 61 K 45/06**

A 61 K 37/26, C 07 C 125/065
C 07 C 103/46, C 07 C 103/52
/(A61K37/26, 31/27, 31/195,
31/165)

(30) Priority: 30.04.82 JP 73306/82
 14.04.83 JP 65999/83

(43) Date of publication of application:
 09.11.83 Bulletin 83/45

(84) Designated Contracting States:
 DE FR GB

(71) Applicant: **AJINOMOTO CO., INC.**
 5-8, Kyobashi 1-chome, Chuo-ku
 Tokyo 104(JP)

(72) Inventor: **Toyoshima, Shigeshi**
 No. 3-14-22, Funabashi
 Setagaya-ku Tokyo(JP)

(72) Inventor: **Fukushima**
 No. 2-1-10-406, Toyogaoka
 Tama-shi Tokyo(JP)


(72) Inventor: **Seto, Yoshiko**
 No. 1-2-3-406, Natsumidai
 Funabashi-shi Chiba-ken(JP)

(72) Inventor: **Kumashiro, Izumi**
 No. 1071-17, Ichigao-cho Midori-ku
 Yokohama-shi Kanagawa-ken(JP)

(74) Representative: **Bond, Bentley George et al,**
Haseltine Lake & Co. 28 Southampton Buildings
Chancery Lane
London WC2A 1AT(GB)

(54) Pharmaceutical composition.

(57) Phenylalanine derivatives having the general formula:



and their non-toxic salts, have been found to promote the absorption of medicinal substances such as insulin. In the above formula, R¹ is a hydrogen atom, a fluorine atom, a nitro group, a hydroxyl group or a hydroxyl group protected by an esterifying group, X is -CO- or -SO₂-, -Y- is a straight bond, a lower alkylene group, a substituted or unsubstituted vinylene group, or a group having the formula -CH₂-O- or -O-CH₂-, and R² is a substituted or unsubstituted phenyl or naphthyl group; or the group R²-Y-CO- is an N-benzyloxy-carbonylphenylalanyl group, an N-benzyloxycarbonyl-4-fluorophenylalanyl group or an N-(m-methoxycinnamoyl)phenylalanyl group.


EP 0 093 551 A2

-1-

PHARMACEUTICAL COMPOSITION

This invention relates to a novel pharmaceutical composition or preparation comprising at least one phenylalanine derivative as an absorption promoter, and a medicinal substance. In accordance with the invention the absorption of medicinal substances in oral or rectal administration is improved.

The phenylalanine derivative used according to the invention is a compound represented by the general formula (I):



wherein R^1 is a hydrogen atom, a fluorine atom, a nitro group, a hydroxyl group or a hydroxyl group protected by an esterifying group, X is -CO- or $\text{SO}_2\text{-}$, -Y- is a straight bond (i.e. the group $\text{R}^2\text{-Y-X-}$ is R-X-), a lower alkylene group, a substituted or unsubstituted vinylene group, or a group having the formula $\text{-CH}_2\text{-O-}$ or $\text{-O-CH}_2\text{-}$, and R^2 is a substituted or unsubstituted phenyl or naphthyl group; or the group $\text{R}^2\text{-Y-CO-}$ is an N-benzyloxycarbonylphenylalanyl group, an N-benzyloxycarbonyl-4-fluorophenylalanyl group or an N-(m-methoxycinnamoyl)phenylalanyl group; or a non-toxic salt thereof.

0093551

-2-

An example of a hydroxyl group protected by an esterifying group is a benzyloxycarbonyl group. Examples of the group R² include phenyl and naphthyl groups which may have, as a substituent, a halogen atom (such as a chlorine or fluorine atom), a nitro group, a lower alkyl group (such as a methyl or trifluoromethyl group) or a lower alkyloxy group (such as a methoxy group).

The term "lower" herein usually means a group having up to 4 carbon atoms, but includes a group having up to about 10 carbon atoms such as a group having up to 8 carbon atoms of formula (I) are:


- Examples of compounds of formula (I) are:
- S-1: N-[(1-naphthyl)acetyl]-L-phenylalanine
 - 15 S-2: N-[(4-nitrophenyl)acetyl]-L-phenylalanine
 - S-3: N-cinnamoyl-L-phenylalanine
 - S-4: N,O-bis-(benzyloxycarbonyl)-L-tyrosine
 - 20 S-5: N-phenoxyacetyl-L-phenylalanine
 - S-6: N-benzyloxycarbonyl-L-phenylalanine
 - S-7: N-(4-phenylbutyryl)-L-phenylalanine
 - S-8: N-phenoxyacetyl-D-phenylalanine
 - S-9: N-benzyloxycarbonyl-L-phenylalanine
 - S-10: N-(1-naphthoxy)acetyl-L-phenylalanine
 - 25 S-11: N-[(2-naphthoxy)acetyl]-L-phenylalanine
 - S-12: N-[(4-chlorophenoxy)acetyl]-L-phenylalanine
 - S-13: N-benzoyl-L-phenylalanine
 - S-14: N-benzyloxycarbonyl-L-tyrosine
 - S-15: N-benzyloxycarbonyl-L-phenylalanine
 - 30 S-16: N-(4-methoxybenzyloxycarbonyl)-L-phenylalanine
 - S-17: N-benzyloxycarbonyl-D-phenylalanine
 - S-18: N-benzoylbenzyloxycarbonyl-L-phenylalanine
 - S-19: N-(4-fluorobenzyloxycarbonyl)-L-phenylalanine
 - S-20: N-benzyloxycarbonyl-L-phenylalanine
 - S-21: N-benzyloxycarbonyl-D-phenylalanine
 - 35 S-22: N-benzyloxycarbonyl-L-phenylalanine
 - S-23: N-benzyloxycarbonyl-4-fluoro-DL-phenylalanine

DL-phenylalanine


- S-24: N-(4-chlorocinnamoyl)-L-phenylalanine
 S-25: N-(4-chlorocinnamoyl)-D-phenylalanine
 S-26: N-(4-fluorocinnamoyl)-L-phenylalanine
 5 S-27: N-(4-methylcinnamoyl)-L-phenylalanine
 S-28: N-(4-trifluoromethylcinnamoyl)-L-phenylalanine
 S-29: N-(3-methoxycinnamoyl)-L-phenylalanine
 S-30: N-(3-trifluoromethylcinnamoyl)-L-phenylalanine
 S-31: N-(α -fluorocinnamoyl)-L-phenylalanine
 10 S-32: N-(3-methoxycinnamoyl)-L-phenylalanyl-L-phenylalanine
 S-33: N-(4-toluenesulfonyl)-L-phenylalanine
 S-34: N-(4-toluenesulfonyl)-DL-phenylalanine
 S-35: N-(4-trifluoromethylcinnamoyl)-D-phenylalanine
 15 S-36: N-(3-trifluoromethylcinnamoyl)-D-phenylalanine.

The above code numbers "S-1 to S-36" are our own code numbers. These code numbers are used in the description hereinbelow.

- The compounds having formula (I) are unique in
 20 that they can be used to promote the absorption of medicinal substances. Phenylalanine per se, N-acetylphenylalanine and lower alkyl esters or amides of the acids of formula (I), are not useful as
 absorption promoters. The compounds of formula (I)
 25 have asymmetric carbon atoms and may be in D-form, in L-form or in DL-form depending upon the specific combination of substituents. The phenylalanine derivatives used in the present invention are known or novel, and can be prepared by conventional N-acylation
 30 techniques, for example by reaction of a compound having the formula:



wherein R^1 is as defined above, with a compound having the formula:



wherein R^2 , Y and X are as defined above.

5 The phenylalanine derivatives of the present invention may be in a form of a salt, such as a metal salt (for example a sodium, potassium, lithium or calcium salt) or a salt with an organic base which is pharmaceutically acceptable. As the organic base,
10 there can be adopted amines such as ammonia (ammonium salt), dicyclohexylamine and N-methyl-D-glucamine, and basic amino acids such as lysine and arginine.

 The phenylalanine derivative of the present invention is administered orally or rectally, together
15 with the medicinal substance. In case of insulin, not only does the derivative promote the absorption of insulin but it also inhibits the degradation of insulin in the presence of trypsin and chymotrypsin.

 Particularly, the oral or rectal administration
20 of insulin for the treatment of diabetes mellitus has not been clinically established yet, and the development of an insulin-absorption promoter that permits extended and convenient use for humans is needed.

 The medicinal substances are, for example,
25 polypeptides or derivatives thereof, or analogues of these compounds, which have two or more hydrophobic amino acid residues close to each other or in a cluster at one or more regions so that the said residues interact non-covalently with the hydrophobic portions
30 of the adjuvant. For example, there is used a soluble globular protein having a cluster or clusters of hydrophobic amino acid residues on the surface, such as insulin, insulin-like growth factor I, insulin-like growth factor II, pancreatic polypeptide, a cyclic
35 peptide having two or more hydrophobic amino acid residues close to each other or in a cluster, such as cyclic peptide hormones, and the preferred

conformation which is induced by the presence of the adjuvant from a random coil or other forms of the polypeptide and its derivatives and their analogues, and having two or more hydrophobic amino acid residues
5 close to each other or in a cluster at one or more regions such as peptide hormones and effectors.

The absorption promoter of the present invention, i.e. the phenylalanine derivative, is usually employed on the range of from 0.1 - 2000 mg, preferably 0.2
10 to 500 mg, to 25U of the medicinal substance (for example insulin).

The absorption promoter may be administered in composition form with the medicinal substance.

Regarding the form of the composition, the
15 phenylalanine derivative can be used by formulating it into a preparation such as a tablet, a capsule, an elixir solution, a suspension, etc.

The phenylalanine derivative and the medicinal substance such as insulin can be administered to a
20 human subject necessitating such treatment in a dosage range of from 0.1 to 1000 mg per subject, generally several times a day, that is, in a total daily dosage of 0.2 to 2000 mg. The dosage varies according to the seriousness of disease, the body weight of the
25 subject, and other factors known by those skilled in the art.

The foregoing typical combinations of drug are formulated into pharmaceutical compositions as stated below. Usually about 0.2 to 500 mg of the phenylalanine
30 derivative and the medicinal substance such as insulin, are blended into a unit dosage form generally acknowledged or required for pharmaceutical practice, together with a pharmaceutically acceptable vehicle, carrier, excipient, binder, antiseptic, stabilizer,
35 flavouring, and so forth. The amount of each active substance in these compositions or preparations is adjusted in such a way as to give an appropriate dosage

-6-


of the prescribed range.
Specific materials which can be incorporated into tablets, capsules, and so forth are as follows:

- 5 binders such as traganth, gum arabic, cornstarch, cellulose; swelling agents such as microcrystalline gelatinized starch and arginine acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose and saccharin; and flavourings such as peppermint, oil from Gaultheria adenothrix Maxim, and cherry.
- 10 Enteric coating is preferably carried out. For example, as a pre-coating agent for forming an undercoat and hydroxyphenylmethylcellulose (8%) aqueous solution may be used. When the unit dosage form of the preparation is a capsule, a liquid carrier such as a fatty oil can further be incorporated in the foregoing types of materials. Various other materials can be present as a coating material or in order to vary the physical form of the unit dosage forms according to other methods. For example, tablets can be coated with shellac and/or sugar. Syrups or elixirs can contain an active compound, sucrose as a sweetener, methylparaben or propylparaben as antiseptics, a colouring agent, or a flavouring agent such as cherry and orange flavoring.
- 25 Aseptic compositions can be formulated according to the usual practice for the preparation of pharmaceutical dosage forms, in which practice an active substance is dissolved or suspended in a vehicle such as water.
- 30 A buffer, antiseptic, or an antioxidant can further be incorporated as the occasion demands.

The following Examples illustrate the invention:

Example 1

Production of compound "S-6":



5

4-Nitro-L-phenylalanine (21 g) was dissolved in 10% NaOH (10 ml), and an ethyl ether solution of phenoxyacetyl chloride (1.7g) and an aqueous Na_2CO_3 solution prepared from Na_2CO_3 (2.7 g) and water (25 ml) were alternatively added stepwise thereto while stirring at room temperature over a period of 20 minutes. After that, the mixture was stirred at room temperature for 3 hours, and then acidified with dilute HCl to precipitate crystals. The crystals were filtered, washed with water, and re-crystallized from dioxan to obtain N-phenoxyacetyl-4-nitro-L-phenylalanine (2.4 g) as needles having a melting point of 147°C (2.4 g).


Elementary analysis:

20	Calc.	C 59.30%, H 4.68%, N 8.14%
	Found	C 59.47%, H 4.51%, N 8.03%.

Example 2

Production of compound "S-8":

25



4-Phenylbutyric acid (25 g) was dissolved in chloroform (500 ml), and N-hydroxysuccinimide (17.3 g) was added thereto. N,N'-dicyclohexylcarbodiimide (31 g) was added in portions to the mixture with ice-cooling while stirring. The mixture was stirred for 1 hour under cooling and then for 7 hours at room temperature. After the addition of glacial acetic acid (10 ml), the mixture was stirred for 1 hour, the insoluble matter was removed by filtration and

the filtrate was evaporated to dryness under reduced pressure. The residue was allowed to recrystallize from ethyl acetate to obtain 4-phenylbutyric acid N-hydroxysuccinimide ester (35 g) having a melting point of 82°C.

The above ester (13 g) was dissolved in chloroform (200 ml). This solution was added dropwise to a solution obtained by dissolving L-phenylalanine (16.5 g) and Na_2CO_3 (15.9 g) in water (150 ml) while stirring at room temperature. After that, the mixture was stirred for 7 hours and the insoluble matter was acidified to a pH of 1.0 with 6N HCl. The precipitated crystals were filtered, washed with water, and re-crystallized from 90% aqueous methanol to obtain N-(4-phenylbutyroyl)-L-phenylalanine (11.2 g) having a melting point of 178°C.

Elementary analysis:

Calc. C 73.28%, H 6.79%, N 4.49%

Found C 73.24%, H 6.94%, N 4.46%

Optical rotation:

$[\alpha]_D^{26} = +8.33^\circ$ (C = 1, acetone)


In the same manner, the compounds listed in the following Table 1 were obtained.

Table 1

	Molecular Formula	m.p. (°C)	Optical rotation
S-24	$\text{C}_{18}\text{H}_{16}\text{ClNO}_3$	155 - 158	$[\alpha]_D^{30} - 31.02^\circ$ (C = 1, MeOH)
S-25	"	157 - 159	$[\alpha]_D^{30} + 31.20^\circ$ (C = 1, MeOH)
S-27	$\text{C}_{19}\text{H}_{19}\text{NO}_3$	135 - 140	$[\alpha]_D^{25} - 35.89^\circ$ (C = 1, MeOH)
S-30	$\text{C}_{19}\text{H}_{16}\text{F}_3\text{NO}_3$	158 - 160	$[\alpha]_D^{20} - 19.10^\circ$ (C = 1, MeOH)
S-31	$\text{C}_{18}\text{H}_{16}\text{FNO}_3$	145 - 148	$[\alpha]_D^{20} - 50.98^\circ$ (C = 1, MeOH)
S-36	$\text{C}_{19}\text{H}_{16}\text{F}_3\text{NO}_3$	157 - 160	$[\alpha]_D^{20} + 19.03^\circ$ (C = 1, MeOH)

Example 3

Production of compound "S-11":



L-Phenylalanine (0.1 mole) was dissolved in 2N NaOH (50 ml) and ethyl ether (20 ml) was added thereto. To the mixture, while stirring vigorously with ice-cooling, the desired naphthoxyacetyl chloride (0.1 mole) and 2N NaOH (100 ml) in small portions were added. The mixture was stirred for 3 hours at a room temperature and washed once with ethyl ether. The aqueous layer was adjusted to a pH of 2 with 4N HCl to precipitate crude crystals. The crystals were placed on a filter paper, dried and re-crystallized with from ethylacetate-petroleum ether.

Compound "S-12" was produced in the same manenr. The results in respect of compounds "S-11" and "S-12" are given in the following Table 2.

Table 2

Compound	Melting Point (°C)	$[\alpha]_D^{20}$ (C = 1, methanol)	Yield of Purified Crystals (%)
S-11	137 - 142	-10.6°	33
S-12	173 - 176	+25.1°	36

Example 4

Production of compound "S-21":

Z-Phe^L-Phe^D

D-Phenylalanine (17.3 g) and NaHCO₃ (17.6 g) were added to water (150 ml).

N-Benzyloxycarbonyl-L-phenylalanine N-hydroxy-succinimide ester (27.7g) was dissolved in tetrahydro-

furan (150 ml), and the resulting solution was added to the above aqueous solution at room temperature. The mixture was reacted overnight. To the reaction solution, water (200 ml) was added and then the aqueous phase was adjusted to a pH of 2 with cooled 4N HCl. The desired product was extracted with ethyl acetate (500 ml). The organic layer was washed first with 1N HCl and then with saturated aqueous NaCl solution, and dried over anhydrous magnesium sulphate. The solution was evaporated to dryness under reduced pressure. The resulting residue (28.0 g) was re-crystallized from ethyl acetate/n-hetane to obtain the required compound (20.3 g, yield: 65%).

In the same manner, compounds "S-22", "S-23" and "S-32" were obtained.

The melting points and optical rotations of these compounds are given in Table 3.

Table 3

Compound	Molecular formula	m.p. (°C)	Optical Rotation
S-21	$C_{26}H_{26}N_2O_5$	119 - 125	$[\alpha]_D^{17} = -34.2^\circ$ (C = 1, EtOH)
S-22	$C_{26}H_{25}FN_2O_5$	158 - 163	$[\alpha]_D^{23} = +13.9^\circ$ (C = 1, EtOH)
S-23	$C_{26}H_{25}FN_2O_5$	133 - 135	$[\alpha]_D^{23} = -19.5^\circ$ (C = 1, EtOH)
S-32	$C_{28}H_{28}N_2O_5$	189 - 191	$[\alpha]_D^{22} = -24.0$ (C = 1, DMF)

Example 5

The absorption promoters listed in Table 4 were dissolved or suspended in 0.5% CMC-0.05M tris-HCl buffers (pH:7.8) and the solutions or suspensions were mixed with aqueous insulin solution. Female ICR-CD-1 mice, 5 to 7 weeks old, were orally administered with predetermined amounts of the mixtures. A predetermined duration later, the percent decrease in blood glucose and the degree of elevation of blood

insulin as compared with a control group were measured. The results are shown in Table 4.

The symbol "Z" in the structural formulae in the Table (and in Example 4 above) represents a benzyloxycarbonyl group. The upper figures in the right hand columns represent the percent decrease in blood glucose and the lower parenthesized figures indicate the degree of elevation in blood insulin.

10

15

20

25

30

35

Table 4







Compound	Structure	Dose with Insulin 2.5 U/10 g (Body Weight)	1) Decrease in Blood Glucose (%) 2) Degree of Elevation of Blood Insulin	
			Time (minutes)	
			30	60
S-1		6.0 mg/10 g	84.9 (56.4)	75.4 (60.0)
S-2	 (DL-)	6.0 mg/10 g	23.2 (>119)	60.0 (89.7)
S-3		6.0 mg/10 g	84.4 (34.2)	84.3 (68.1)
S-4	 (L-)	3.0 mg/10 g	52.7 (6.54)	31.1 (2.04)
S-5		12.5 mg/10 g	57.9 (88.5)	33.5 (18.0)
S-6	 (L-)	3.1 mg/10 g	21.5 (20.6)	44.7 (21.8)
S-7	Z - PheL - PheL	3.0 mg/10 g	70.0 (7.72)	40.6 (9.35)

Table 4 (Continued)







Compound	Structure	Dose with Insulin 2.5 U/10 g (Body Weight)	1) Decrease in Blood Glucose (%) 2) Degree of Elevation of Blood Insulin	
			Time (minutes)	
			30	60
S-8		6.0 mg/10 g	57.1 (7.31)	35.6 (9.64)
S-9		3.0 mg/10 g	37.3 (11.8)	29.7 (2.67)
S-10	Z-Phe ^L -Tyr ^L	6.0 mg/10 g	61.5 (41.9)	43.4 (4.85)
S-11		6.0 mg/10 g	54.0 (11.8)	59.7 (5.07)
S-12		6.0 mg/10 g	50.8 (6.05)	66.8 (5.62)
S-13		1.5 mg/10 g	31.9 (43.4)	18.5 (9.82)
S-14		6.0 mg/10 g	35.2 (6.31)	37.8 (3.31)

Table 4 (Continued)



Compound	Structure	Dose with Insulin 2.5 U/10 g (Body Weight)	1) Decrease in Blood Glucose (%) 2) Degree of Elevation of Blood Insulin	
			Time (minutes)	
			30	60
S-15	Z - Phe ^L	3.0 mg/10 g	37.5 (3.43)	60.7 (2.36)
S-16	Z - Tyr ^L	6.0 mg/10 g	31.0 (50.0)	27.2 (2.99)
S-17		3.0 mg/10 g	64.8 (14.4)	50.6 (21.2)
S-18	Z - Phe ^D	6.0 mg/10 g	52.3 (6.79)	67.2 (10.6)
S-20	Z - Phe ^D - Phe ^L	1.5 mg/10 g	22.4 (2.33)	32.7 (2.46)
S-21	Z - Phe ^L - Phe ^D	6.0 mg/10 g	42.6 (14.9)	32.7 (5.26)
S-22		3.0 mg/10 g	63.1 (-)	51.9 (-)

Table 4 (Continued)

Compound	Structure	Dose with Insulin 2.5 U/10 g (Body Weight)	1) Decrease in Blood Glucose (%) 2) Degree of Elevation of Blood Insulin	
			Time (minutes)	
			30	60
S-23	$\begin{array}{c} \text{Z-Phe}^{\text{L}}-\text{N}^{\text{H}}-\text{CO}_2\text{H} \\ \\ \text{C}_6\text{H}_4 \\ \\ \text{F} \end{array} \quad (\text{DL-})$	3.0 mg/10 g	67.5 (-)	39.4 (-)
S-24	$\text{Cl}-\text{C}_6\text{H}_4-\text{CH}=\text{CH}-\text{CO}-\text{Phe}^{\text{L}}$	1.5 mg/10 g	37.1 (5.46)	27.4 (3.04)
S-25	$\text{Cl}-\text{C}_6\text{H}_4-\text{CH}=\text{CH}-\text{CO}-\text{Phe}^{\text{D}}$	1.5 mg/10 g	34.9 (-)	29.5 (-)
S-27	$\text{Me}-\text{C}_6\text{H}_4-\text{CH}=\text{CH}-\text{CO}-\text{Phe}^{\text{L}}$	1.5 mg/10 g	61.5 (7.76)	34.4 (1.0)
S-30	$\text{F}_3\text{C}-\text{C}_6\text{H}_4-\text{CH}=\text{CH}-\text{CO}-\text{Phe}^{\text{L}}$	3.0 mg/10 g	48.8 (-)	44.4 (-)
S-31	$\text{C}_6\text{H}_5-\text{CH}=\text{CF}-\text{CO}-\text{Phe}^{\text{L}}$	3.0 mg/10 g	33.5 (-)	72.5 (-)
S-32	$\text{MeO}-\text{C}_6\text{H}_4-\text{CH}=\text{CH}-\text{CO}-\text{Phe}^{\text{L}}$	3.0 mg/10 g	- (-)	23.8 (4.55)
S-33	TS - Phe ^L	3.0 mg/10 g	51.6 (18.1)	21.4 (6.48)

Table 4 (Continued)


Compound	Structure	Dose with Insulin 2.5 U/10 g (Body Weight)	1) Decrease in Blood Glucose (%) 2) Degree of Elevation of Blood Insulin	
			Time (minutes)	
			30	60
S-34	Ts - Phe ^{DL}	6.0 mg/10 g	27.3 (13.8)	93.1 (6.52)
S-36		3.0 mg/10 g	52.0 (-)	49.1 (-)

Table 4 shows the effectiveness of the absorption promoters of the present invention administered orally, but it should be understood that the same results are obtained by using the absorption promoters as

5 a conventional suppository preparation, together with insulin. The absorption promoters of the present invention are very useful in that they enable clinical insulin therapy by the oral or perenteral (e.g. rectal) administration.

10 Example 6

Toxicity studies of phenylalanine derivatives of the invention, in respect of their oral IN potentiating activity in female CD-1(ICR) mice, were carried out, the derivatives being suspended in 0.5% CMC.

15 The results are given in the following Table 5.

20

25

30

35

5

10

15

20

25

30

35

Table 5

Compound	LD ₅₀ (mg/kg)
N-Phenoxyacetyl-L-phenylalanine	>4000
N-(1-Naphthyloxy)acetyl-L-phenylalanine	>4000
N-(2-Naphthyloxy)acetyl-L-phenylalanine	>4000
N-(4-Chlorophenoxy)acetyl-L-phenylalanine	>3500
N-Benzylloxycarbonyl-L-phenylalanine	>2750
N-Benzylloxycarbonyl-D-phenylalanine	>4000
N-p-Methoxybenzylloxycarbonyl-L-phenylalanine	750
N-Benzylloxycarbonyl-L-phenylalanyl-L-phenylalanine	>3000
N-Benzylloxycarbonyl-L-phenylalanyl-L-tyrosine	>3000
N-Cinnamoyl-L-phenylalanine	>2500

Example 7 (Preparation of Tablets)

Porcine insulin (0.577 g, 15000 U, Zn content = 0.5%) was dissolved in 0.05 N HCl (30 ml) and the thus obtained solution was diluted with distilled
5 water (30 ml).

The compound "S-27" (6g) was dissolved in 0.1N NaOH (200 ml) and the pH was adjusted to 7.5 by the addition of 0.1N HCl. The solution was diluted with phosphate buffer (0.02M, pH 7.5) to a volume of 600
10 ml.

The insulin solution produced as above was added dropwise to the "S-27" solution maintained at 20°C and with vigorously stirring, the resulting solution was adjusted to pH 7.5, and immediately was freeze-
15 dried.

Tablets were prepared from the freeze-dried material (25 mg), pregelatinized starch (82 mg), microcrystalline cellulose (82 mg), and magnesium stearate (1 mg). Then, enteric coating tablets were prepared by a
20 conventional method using an aqueous solution of hydroxyphenylmethylcellulose (8%) as a pre-coating agent for forming an undercoat and an aqueous solution of hydroxypropylmethylcellulose phthalate (10%) and polyacetyne (3%) as a coating agent.

25 Example 8 (Preparation of capsules)

To glacial acetic (250 ml), the compound "S-22" (30 g) was added and dissolved by heating. Porcine insulin (2 g, 52000U, Zn content = 0.5%) was added in small portions to the above solution cooled to
30 20°C, with stirring, and dissolved therein. From the solution the acetic acid was distilled off under reduced pressure and at the same temperature.

To thus obtained solid residue, n-hexane (100 ml) was added, and the solid residue was pulverized,
35 put on a filter, and washed with n-hexane. Then the n-hexane adhering to the powder was evaporated under reduced pressure. The powder was dried under

-20-

reduced pressure in the presence of solid NaOH.

Dry packed capsules containing 50 mg per capsule of active ingredient were prepared:

	the above powder	50 mg
5	lactose	149 mg
	magnesium stearate		1 mg
	capsule	200 mg.

The powder was first reduced to a No. 60 powder, and the lactose and magnesium stearate were passed through a No. 60 sieve cloth to fall onto the powder and mixed sufficiently with it. The mixture was packed into No. 1 dry gelatin capsules.

15

20


25

30

35

CLAIMS

1. A pharmaceutical composition characterized in that it comprises (a) at least one medicinal substance and (b) a phenylalanine derivative having the following
5 general formula:



10

- wherein R^1 is a hydrogen atom, a fluorine atom, a nitro group, a hydroxyl group or a hydroxyl group protected by an esterifying group, X is -CO- or $\text{-SO}_2\text{-}$,
-Y- is a straight bond, a lower alkylene group, a
15 substituted or unsubstituted vinylene group, or a group having the formula $\text{-CH}_2\text{-O-}$ or $\text{-O-CH}_2\text{-}$, and R^2 is a substituted or unsubstituted phenyl or naphthyl group; or the group $\text{R}^2\text{-Y-CO-}$ is an N-benzyloxycarbonyl-phenylalanyl group, an N-benzyloxycarbonyl-4-fluoro-
20 phenylalanyl group or an N-(m-methoxycinnamoyl)phenylalanyl group; or a non-toxic salt thereof.


2. A composition as claimed in claim 1, wherein said medicinal substance is at least one substance selected from polypeptides, their derivatives, and
25 the analogues of these compounds, which have two or more hydrophobic amino acid residues close to each other or in a cluster at one or more regions so that the said residues interact non-covalently with the hydrophobic portions of the adjuvants.

- 30 3. A composition as claimed in claim 1 or 2, wherein said medicinal substance is at least one substnace selected from (1) a soluble globular protein having a cluster or clusters of hydrophobic amino acid residues on the surface, (2) a cyclic peptide
35 having two or more hydrophobic amino acid residues close to each other or in a cluster; and (3) the preferred conformation which is induced by the presence

of the adjuvant from a random coil or other forms of the polypeptide and its derivatives and their analogues, and has two or more hydrophobic amino acid residues close to each other or in a cluster
5 at one or more regions.


4. A composition as claimed in claim 3, wherein said medicinal substance is at least one substance selected from insulin, insulin-like growth factor I, insulin-like growth factor II, pancreatic poly-
10 peptide, a cyclic peptide hormone, a peptide hormone, and a peptide effector.

5. The use of a phenylalanine derivative having the general formula:



wherein R^1 , R^2 , X and Y are as defined in claim 1,
20 or a non-toxic salt thereof, as a promotor of the absorption of a medicinal substance.

6. A phenylalanine derivative having the general formula:



wherein R^1 , R^2 and Y are as defined in claim 1, or
30 a non-toxic salt thereof.

⑫ **EUROPEAN PATENT APPLICATION**

⑰ Application number: 83302290.8

⑱ Date of filing: 22.04.83

⑮ Int. Cl.⁴: **A 61 K 45/06, A 61 K 37/26,**
C 07 C 125/065, C 07 C 103/46,
C 07 C 103/52
//
(A61K37/26, 31:27,
31:195, 31:165)

⑳ Priority: 30.04.82 JP 73306/82
14.04.83 JP 65999/83

㉓ Date of publication of application: 09.11.83
Bulletin 83/45

㉔ Designated Contracting States: DE FR GB

㉖ Date of deferred publication of search
report: 21.11.85 Bulletin 85/47


㉗ Applicant: **AJINOMOTO CO., INC., 5-8,**
Kyobashi 1-chome, Chuo-ku, Tokyo 104 (JP)

㉘ Inventor: **Toyoshima, Shigeshi, No. 3-14-22, Funabashi,**
Setagaya-ku Tokyo (JP)
Inventor: **Fukushima, No. 2-1-10-406, Toyogaoka,**
Tama-shi Tokyo (JP)
Inventor: **Seto, Yoshiko, No. 1-2-3-406, Natsumidai,**
Funabashi-shi Chiba-ken (JP)
Inventor: **Kumashiro, Izumi, No. 1071-17, Ichigao-cho**
Midori-ku, Yokohama-shi Kanagawa-ken (JP)

㉙ Representative: **Bond, Bentley George et al, Haseltine**
Lake & Co. 28 Southampton Buildings Chancery Lane,
London WC2A 1AT (GB)

㉚ **Pharmaceutical composition.**

㉛ Phenylalanine derivatives having the general formula:



and their non-toxic salts, have been found to promote the absorption of medicinal substances such as insulin. In the above formula, R¹ is a hydrogen atom, a fluorine atom, a nitro group, a hydroxyl group or a hydroxyl group protected by an esterifying group, X is -CO- or -SO₂-, -Y- is a straight bond, a lower alkylene group, a substituted or unsubstituted vinylene group, or a group having the formula -CH₂-O- or -O-CH₂-, and R² is a substituted or unsubstituted phenyl or naphthyl group; or the group R²-Y-CO- is an N-benzoyloxy-carbonylphenylalanyl group, an N-benzoyloxycarbonyl-4-fluorophenylalanyl group or an N-(m-methoxycinnamoyl) phenylalanyl group.

EP 0 093 551 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

0093551

Application number

EP 83 30 2290

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
Y	CHEMICAL ABSTRACTS, vol 95, no. 24, December 14, 1981, page 374, abstract 209609m Columbus, Ohio, US A. KAMADA et al.: "Study of enamine derivatives on phenylglycine as adjuvants for the rectal absorption of insulin" & Chem. Pharm. Bull. 1981, 29(7), 2012-19 * Abstract*	1,4,5	A 61 K 45/06 A 61 K 37/26 C 07 C 125/065 C 07 C 103/46 C 07 C 103/52// (A 61 K 37/26 31/27 31/195 31/165)
Y	GB - A - 2 095 994 (TOYO JOZO COMPANY) * Claims, page 3, lines 40-64 *	1-5	
P,X	CHEMICAL ABSTRACTS, vol. 100, no. 2, January 9, 1984, page 362, abstract 12583p ./.		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 2)
			A 61 K 45/00 A 61 K 37/00 A 61 K 47/00 C 07 C 103/00 C 07 C 125/00
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-5</p> <p>Claims searched incompletely: 6</p> <p>Claims not searched: 6</p> <p>Reason for the limitation of the search: Formula in claim 6 is different of formula of claim 1 and relates to compounds not covered by the description.</p>			
Place of search The Hague		Date of completion of the search 21-06-1985	Examiner MOREAU
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO Form 1505.1. 03/82



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,X	Columbus, Ohio, US T. YAGI et al.: "Insulin suppository: enhanced rectal absorption of insulin using an enamine derivative as a new promoter" & J. Pharm. Pharmacol. 1983, 35 (3), 177-8 * Abstract *	1-5	
	CH--		
	CHEMICAL ABSTRACTS, vol.101, no. 15, October 8, 1984, page 108 abstract 123533n Columbus, Ohio, US K: FUKUSHIMA et al.: "Oral administration of insulin in combination with amino acid derivatives in animal experiments" & Int. Congr. Ser. - Excerpta Med. 1983, 607 (Curr. Future Ther. Insulin), 257-62 * Abstract *	1-5	TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
